This Is What Whales Are Betting On Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
A significant investor has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN), with 70% of recent trades being bearish. The targeted price range for the company over the last three months has been $690.0 to $810.0. The current price of REGN is up 1.11% at $726.48. Analysts from Truist Securities, Baird, Cantor Fitzgerald, and Barclays have maintained their ratings, with price targets ranging from $760 to $1045.

July 17, 2023 | 7:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron Pharmaceuticals has seen a bearish stance from a significant investor, with 70% of recent trades being bearish. Analysts have maintained their ratings, with price targets ranging from $760 to $1045.
The bearish stance from a significant investor, along with the fact that 70% of recent trades have been bearish, could potentially lead to a decrease in the stock price. However, analysts have maintained their ratings and have set high price targets, indicating potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100